3 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 1 | Terminated 1 |
Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) A6 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Ã…ngstrom Pharmaceuticals | 5 | 2014-02-01 | 2016-07-13 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia (1) · Lymphoma (1) · Neoplasms (1) · Recurrence (1)
Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Leukemia (1) · Neoplasms (1)
Alemtuzumab (1) · Methylprednisolone (1) · dubermatinib (1) · ofatumumab (1)
Dana-Farber Cancer Institute (1) · Sumitomo Pharma America, Inc. (1) · Ã…ngstrom Pharmaceuticals (1)
United States (3)
Jennifer R Brown, MD PhD (1) · Michael Choi, MD (1) · Phillip Komarnitsky (1)